RA
CDMO

Royce & Associates’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Royce & Associates’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-789,227
Closed -$8.98M – 912
2024
Q3 		$8.98M Buy
789,227
+57,111
+8% +$573K 0.08% 339
2024
Q2 		$5.23M Buy
732,116
+93,816
+15% +$718K 0.05% 470
2024
Q1 		$4.28M Buy
638,300
+140,230
+28% +$965K 0.04% 529
2023
Q4 		$3.24M Buy
498,070
+220,070
+79% +$1.42M 0.03% 576
2023
Q3 		$2.62M Sell
278,000
-25,000
-8% -$301K 0.03% 609
2023
Q2 		$4.23M Hold
303,000
– – 0.04% 532
2023
Q1 		$5.68M Buy
303,000
+47,000
+18% +$772K 0.06% 455
2022
Q4 		$3.53M Buy
256,000
+41,600
+19% +$637K 0.04% 557
2022
Q3 		$4.1M Sell
214,400
-115,300
-35% -$2.1M 0.05% 487
2022
Q2 		$5.03M Sell
329,700
-48,500
-13% -$717K 0.05% 472
2022
Q1 		$7.7M Buy
378,200
+189,500
+100% +$3.86M 0.07% 433
2021
Q4 		$5.51M Sell
188,700
-38,900
-17% -$1.11M 0.04% 545
2021
Q3 		$4.91M Sell
227,600
-3,400
-1% -$82.1K 0.04% 587
2021
Q2 		$5.92M Sell
231,000
-44,200
-16% -$944K 0.04% 569
2021
Q1 		$5.02M Sell
275,200
-3,300
-1% -$54.8K 0.03% 596
2020
Q4 		$3.21M Buy
278,500
+21,500
+8% +$197K 0.03% 644
2020
Q3 		$1.96M Hold
257,000
– – 0.02% 682
2020
Q2 		$1.69M Sell
257,000
-42,000
-14% -$234K 0.02% 703
2020
Q1 		$1.53M Sell
299,000
-35,000
-10% -$212K 0.02% 656
2019
Q4 		$2.56M Hold
334,000
– – 0.02% 648
2019
Q3 		$1.77M Buy
334,000
+34,000
+11% +$211K 0.02% 728
2019
Q2 		$1.68M Buy
+300,000
New +$1.24M 0.02% 758

Other funds holding CDMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
AltraVue Capital Bellevue, Washington $1.39B AUM 53.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Royce & Associates's CDMO Position: Q4 2024 in Review

Royce & Associates sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q4 2024, closing a stake of 789,227 shares — an estimated $8.98M sold.

Royce & Associates first reported a position in CDMO in Q2 2019 and held it in 22 quarters. The position peaked at $8.98M in Q3 2024. 195 funds tracked by Wall St. Rank hold CDMO as of Q4 2024.

  • Royce & Associates reported no remaining Avid Bioservices, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Royce & Associates sold 789,227 Avid Bioservices, Inc. Common Stock shares in Q4 2024, an estimated $8.98M.
  • Royce & Associates first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2019 and held it in 22 quarters.
  • Royce & Associates's Avid Bioservices, Inc. Common Stock position peaked at $8.98M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q4 2024.

Based on Royce & Associates's 13F filing for Q4 2024, filed 10 Feb 2025.